. N-glycosylation of PD-1 had no effect on the interaction with nivolumab (a) and pembrolizumab (b). A flow cytometric analysis of antibodies binding to WT PD-1 or various glycosylation sites mutated proteins (N49A, N58A, N74A, and N116A) expressed on the cell surface of HEK 293 cells. Plasmids expressing WT PD-1 or mutant proteins fused with EGFP were used for transfection. Mock-transfected HEK 293 cells were used as negative control (NC).
Supplementary Figure 2
Supplementary Figure 2 . Competitive binding of MW11-h317 Fab with PD-1 ligand PD-L2. (a) Superposition of the PD-1/ MW11-h317 Fab complex structure with PD-1/PD-L2 complex structure (PDB ID: 3BP5). MW11-h317 H chain is shown in green, L chain in cyan and PD-L2 in magenta. PD-1 is shown as surface representation in gray. (b) Binding surface of PD-1 with MW11-h317 or PD-L2. The residues in contact with MW11-h317 are shown in green, whereas residues in contact with PD-L2 are shown in magenta, and the overlapping residues bounded by both MW11-h317 and PD-L2 are shown in orange.
Supplementary Tables
Supplementary Table 1 PD-1 binding epitopes in three antibodies. 
